Sabinsa has been granted a US patent on the company’s shelf stable probiotic LactoSpore® in combination with cranberry seed fibers. The granted patent (US9717766) discloses a method of increasing the viable colony count of Bacillus coagulans MTCC 5856 in a synbiotic composition containing natural plant fibers from Vaccinium oxycoccos (Cranberry). The cranberry fibers in this composition were observed to increase the viable count of Bacillus coagulans MTCC 5856.

This combination product is sold under the name LactoCran, with the cranberry seed fiber components supplied by Fruit d’Or Nutraceuticals of Quebec, Canada. LactoCran™ provides support for healthy gut and digestive health. The non-lactose, diary-free, non-GMO combination works well in sports nutrition supplements as it contains a rich composition of 16 essential amino acids and 8 branch chain amino acids.

This patent, along with the previously granted patent for the management of Irritable Bowel Syndrome, is expected to boost LactoSpore’s popularity and market value.

LactoSpore® is a GRAS probiotic containing Bacillus coagulans MTCC 5856 which is lactose-free and non-GMO. This exceptional probiotic is room temperature stable and does not require refrigeration, ensuring a long product shelf life. Because of its ability to withstand high heat, LactoSpore® has been included in functional baked goods. Clinically studied LactoSpore® can be used in a variety of food and dietary supplements for maintaining gut health and good microbiota.